Fennec Pharmaceuticals Expands Possible TAM Significantly [Seeking Alpha]
Fennec Pharmaceuticals Inc. (FENC)
Last fennec pharmaceuticals inc. earnings: 11/12 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.fennecpharma.com/investor-relations
Company Research
Source: Seeking Alpha
The company faced challenges and delays in obtaining FDA approval but finally launched PEDMARK® in late 2022, and generated $6.5 million in sales in Q3 2023. The company is poised to start selling PEDMARK® in Germany in May or June 2024. Being added to the NCCN's Adolescent and Young Adult Oncology treatment guidelines, could potentially double the TAM, increasing peak year revenue expectations. Fennec Pharmaceuticals - Overview Fennec Pharmaceuticals ( NASDAQ: FENC ) is a small cap, commercial-stage biotech company with a single drug, PEDMARK®. PEDMARK is a unique formulation of sodium thiosulfate specifically developed for pediatric patients. PEDMARK® is FDA-approved to reduce the risk of ototoxicity or hearing loss associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors. The drug is used in children who receive platinum-based chemotherapy. In one study, 60% of children develop irreversible ototoxicity when expose
Show less
Read more
Impact Snapshot
Event Time:
FENC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FENC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FENC alerts
High impacting Fennec Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
FENC
News
- Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC) [Yahoo! Finance]Yahoo! Finance
- Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)GlobeNewswire
- Fennec Pharmaceuticals: A Compelling Single-Asset Growth Story For 2026 [Seeking Alpha]Seeking Alpha
- Adherex Technologies (NASDAQ:FENC) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.MarketBeat
- Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell TumorsGlobeNewswire
FENC
Earnings
- 11/13/25 - Beat
FENC
Sec Filings
- 12/9/25 - Form 8-K
- 12/5/25 - Form 4
- 12/5/25 - Form 144
- FENC's page on the SEC website